

This listing of claims will replace all prior versions of claims in the application.

Listing of Claims: Please amend the claims as follows:

We claim:

Claim 1. (Cancelled)

Claim 2. (Cancelled)

Claim 3. (Cancelled)

Claim 4. (Cancelled)

Claim 5. (Cancelled)

Claim 6. (Cancelled)

Claim 7. (Currently Amended) A pharmaceutical composition which comprises an acceptable vehicle and a combination of at least two peptides, wherein said combination comprises the peptide FALPQYLK (SEQ ID NO: 5) and at least one peptide which is ~~are~~

- (a) the peptide TVY (SEQ ID NO: 1);
- (b) the peptide NMAINPSK (SEQ ID NO: 2);
- (c) the peptide FALPQY (SEQ ID NO: 3); or
- (d) the peptide FPQYLQY (SEQ ID NO: 4) ~~or~~
- ~~(e) the peptide FALPQYLK (SEQ ID NO: 5);~~

wherein said pharmaceutical composition has inhibiting activity on angiotensin converting enzyme (ACE), with IC₅₀ values equal to or less than 60 µM.

Claim 8. (Withdrawn, Currently Amended) The pharmaceutical composition of claim 4 7 which comprises as its active ingredient an effective quantity of the peptide of SEQ ID NO: 5.

Claim 9. (Currently Amended) A food product comprising, in combination with a food base, a combination of at least two peptides, wherein said combination comprises the peptide FALPQYLK (SEQ ID NO: 5) and at least one peptide which is ~~are~~

- (a) the peptide TVY (SEQ ID NO: 1);
- (b) the peptide NMAINPSK (SEQ ID NO: 2);
- (c) the peptide FALPQY (SEQ ID NO: 3); or
- (d) the peptide FPQYLQY (SEQ ID NO: 4) ~~or~~
- ~~(e) the peptide FALPQYLK (SEQ ID NO: 5);~~

wherein said food base comprising said peptides has inhibiting activity on ACE, with IC₅₀ values equal to or less than 60 μ M.

Claim 10. (Currently Amended) The food product according to claim 9 further comprising at least one peptide which is

- ~~(f)~~ (e) the peptide ALNEINQFYQK (SEQ ID NO: 8),
- ~~(g)~~ (f) the peptide ALNEINQFY (SEQ ID NO: 9), or
- ~~(h)~~ (g) the peptide YL (SEQ ID NO: 10).

Claim 11. (Currently Amended) A method of preparation of a pharmaceutical composition having antihypertensive activity comprising

fractioning a tryptic hydrolysate of α_{s2} casein by reverse phase high performance liquid chromatography (HPLC) in a gradient of acetonitrile, obtaining peptide fraction corresponding to peak 1, 2, 3 or 4 collected respectively at 25, 29, 57 or 60 min, wherein:

- peak 1 contains the peptide TVY (SEQ ID NO: 1);
- peak 2 contains the peptide NMAINPSK (SEQ ID NO: 2);
- peak 3 contains the peptide FALPQY (SEQ ID NO: 3);
- peak 4 contains the peptide FPQYLQY (SEQ ID NO: 4) and the peptide FALPQYLK (SEQ ID NO: 5);

wherein said peptides have inhibiting activity on angiotensin converting enzyme (ACE), with IC₅₀ values equal or less than 60 μ M,

and

combining an effective amount of ~~at least two peptides of the peptide~~ the peptide FALPQYLK (SEQ ID NO: 5) and at least one peptide which is SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO:3, or SEQ ID NO:4 ~~SEQ ID NOs: 1-5~~ with a pharmaceutically acceptable vehicle.

Claim 12. (Currently Amended) The food product according to claim 9, wherein said food base comprises a protein, lipid, or a carbohydrate.

Claim 13. (Withdrawn, Currently Amended) A method of inhibiting angiotensin I converting enzyme (ACE) comprising contacting said enzyme with the pharmaceutical composition of claim 7 ~~4~~.

Claim 14. (Withdrawn, Currently Amended) A method of treating hypertension comprising administering to a subject in need thereof an effective amount of the pharmaceutical composition of claim 7 ~~4~~.

Claim 15. (New) The pharmaceutical preparation according to claim 7 further comprising at least one peptide which is

(e) the peptide ALNEINQFYQK (SEQ ID NO: 8);

(f) the peptide ALNEINQFY (SEQ ID NO: 9); or

(g) the peptide YL (SEQ ID NO: 10).